Immutep Reports Positive Phase I Results for First-in-Class LAG-3 Agonist IMP761
Immutep Limited announces a positive update from the placebo-controlled, double-blind first-in-human Phase I study in healthy participants evaluating IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. The single-ascending dose escalation portion of the trial has successfully completed the 2.5 and 7 mg / kg dosing levels of IMP761 with continued positive safety and efficacy data. IMP761 was tolerated well with no treatment-related adverse reactions beyond mild intensity. Additionally, evidence of dose dependent immunosuppressive effects with IMP761 was observed with significant, long-lasting inhibition of the three T-cell-mediated intradermal reactions to a strong foreign antigen at day 2, 9 and 23. Given encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026 including presentation of data at a major medical conference
Discover Tomorrow's Bullish Stocks Today
Analyst Views on IMMP
No data
About IMMP
About the author
Immutep's First LAG-3 Antibody Trial Shows Positive Phase I Results
- Clinical Trial Progress: Immutep's IMP761 has completed the 2.5 and 7 mg/kg dosing levels in a Phase I trial with healthy participants, demonstrating positive safety and efficacy data without serious adverse reactions, indicating its potential in treating autoimmune diseases.
- Immunosuppressive Effects: The drug exhibited dose-dependent immunosuppressive effects, achieving significant and long-lasting inhibition of T-cell-mediated intradermal reactions to a strong foreign antigen on days 2, 9, and 23, potentially offering new treatment avenues for conditions like rheumatoid arthritis.
- Market Opportunity: As a therapeutic target for autoimmune diseases, LAG-3 positions IMP761 to address large markets, including Type 1 diabetes and multiple sclerosis, which could translate into multi-billion dollar opportunities for the company.
- Future Outlook: Immutep plans to continue the trial as scheduled, with additional updates expected in the first half of 2026, further enhancing market interest and investor confidence in this promising program.
ASX Penny Stocks Highlight: DUG Technology Featured Among Three Key Selections
Market Overview: Australian shares are facing challenges due to global tech sector declines, prompting investors to consider penny stocks, which may offer surprising value and stability despite their smaller size.
DUG Technology Ltd: This technology company, with a market cap of A$281.66 million, has shown improvement in financial health, reducing losses significantly over the past five years, and has potential for future growth despite current profitability challenges.
Immutep Limited: A biotechnology firm focused on immunotherapies, Immutep has a market cap of A$552.65 million and is well-positioned financially, with a strong cash position supporting ongoing clinical trials, despite being pre-revenue.
Wagners Holding Company: With a market cap of A$719.01 million, Wagners has demonstrated robust financial health and significant earnings growth, supported by its inclusion in the S&P/ASX Emerging Companies Index, although it faces challenges with long-term liabilities.
